|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/12/21 Nutralife Biosciences, Inc. 10-Q 3/31/20 52:2.1M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 171K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 21K
3: EX-32.1 Certification -- §906 - SOA'02 HTML 17K
10: R1 Document and Entity Information HTML 44K
11: R2 Condensed Consolidated Balance Sheets HTML 96K
12: R3 Condensed Consolidated Balance Sheets HTML 38K
(Parenthetical)
13: R4 Condensed Consolidated Statements of Operations HTML 72K
(Unaudited)
14: R5 Condensed Consolidated Statements of Operations HTML 17K
(Unaudited) (Parenthetical)
15: R6 Condensed Consolidated Statement of Stockholders' HTML 62K
Equity (Unaudited)
16: R7 Consolidated Condensed Statements of Cash Flows HTML 102K
(Unaudited)
17: R8 Nature of Operations and Consolidation HTML 19K
18: R9 Basis of Presentation and Summary of Significant HTML 48K
Accounting Policies
19: R10 Liquidity and Going Concern Considerations HTML 22K
20: R11 Property and Equipment, Net HTML 23K
21: R12 Intangible Asset HTML 21K
22: R13 Accrued Expenses HTML 22K
23: R14 Notes Payable HTML 21K
24: R15 Stockholders' Equity HTML 22K
25: R16 Leases HTML 29K
26: R17 Commitments and Contingencies HTML 19K
27: R18 Subsequent Events HTML 21K
28: R19 Basis of Presentation and Summary of Significant HTML 90K
Accounting Policies (Policies)
29: R20 Basis of Presentation and Summary of Significant HTML 27K
Accounting Policies (Tables)
30: R21 Property and Equipment, Net (Tables) HTML 22K
31: R22 Intangible Asset (Tables) HTML 20K
32: R23 Accrued Expenses (Tables) HTML 21K
33: R24 Leases (Tables) HTML 29K
34: R25 Basis of Presentation and Summary of Significant HTML 24K
Accounting Policies (Details Narrative)
35: R26 Basis of Presentation and Summary of Significant HTML 22K
Accounting Policies - Schedule of Inventories
(Details)
36: R27 Basis of Presentation and Summary of Significant HTML 21K
Accounting Policies - Schedule of Warrants and
Convertible Notes Excluded from Computation of Net
Loss Per Share (Details)
37: R28 Liquidity and Going Concern Considerations HTML 28K
(Details Narrative)
38: R29 Property and Equipment, Net (Details Narrative) HTML 18K
39: R30 Property and Equipment, Net - Summary of Property HTML 26K
and Equipment (Details)
40: R31 Intangible Asset (Details Narrative) HTML 35K
41: R32 Intangible Asset - Schedule of Estimate HTML 31K
Amortization Expense (Details)
42: R33 Accrued Expenses - Summary of Accrued Expenses HTML 27K
(Details)
43: R34 Notes Payable (Details Narrative) HTML 43K
44: R35 Stockholders' Equity (Details Narrative) HTML 60K
45: R36 Leases (Details Narrative) HTML 46K
46: R37 Leases - Schedule of Operating Leases Undiscounted HTML 33K
Future Minimum Lease Payments (Details)
47: R38 Leases - Schedule of Supplemental Cash Flow HTML 18K
Information Related To Leases (Details)
48: R39 Leases - Schedule of Finance Leases Undiscounted HTML 33K
Future Minimum Lease Payments (Details)
49: R40 Subsequent Events (Details Narrative) HTML 35K
51: XML IDEA XML File -- Filing Summary XML 93K
50: EXCEL IDEA Workbook of Financial Reports XLSX 59K
4: EX-101.INS XBRL Instance -- nlbs-20200331 XML 473K
6: EX-101.CAL XBRL Calculations -- nlbs-20200331_cal XML 149K
7: EX-101.DEF XBRL Definitions -- nlbs-20200331_def XML 219K
8: EX-101.LAB XBRL Labels -- nlbs-20200331_lab XML 595K
9: EX-101.PRE XBRL Presentations -- nlbs-20200331_pre XML 425K
5: EX-101.SCH XBRL Schema -- nlbs-20200331 XSD 102K
52: ZIP XBRL Zipped Folder -- 0001493152-21-008537-xbrl Zip 71K
EXHIBIT 31.1
CERTIFICATIONS
I, Edgar Ward, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2020 of NutraLife BioSciences, Inc.; | |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have: | |
| a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| b. | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| c. | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| d. | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and; | |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions); | |
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls. | |
| Dated: April 12, 2021 | /s/ Edgar Ward |
| Edgar Ward | |
| Chief Executive Officer | |
| (principal executive officer, principal financial and accounting officer) |
C:
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 4/12/21 | None on these Dates | ||
| For Period end: | 3/31/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/05/20 Nutralife Biosciences, Inc. 8-K:1,3,5,7 9/30/20 5:3.3M M2 Compliance LLC/FA 2/15/19 Nutralife Biosciences, Inc. DEF 14C 2/15/19 1:1.2M Discount Edgar/FA 11/01/17 Nutralife Biosciences, Inc. 10-12G 30:7.1M Printing & Proxy, LLC/FA |